Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Randomized, Active-Comparator Controlled, Open-Label Trial to Evaluate the Immunogenicity & Safety of Alternate 2-Dose Regimens of Cecolin® Compared to Gardasil® in 9-14 Year-Old Girls in Low and Low-Middle Income Countries

NCT04508309 is registered in ClinicalTrials.gov with PATH as lead sponsor.

NCT NCT04508309
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04508309 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Randomized, Active-Comparator Controlled, Open-Label Trial to Evaluate the Immunogenicity & Safety of Alternate 2-Dose Regimens of Cecolin® Compared to Gardasil® in 9-14 Year-Old Girls in Low and Low-Middle Income Countries
Lead sponsor
PATH
Phase
Phase 3
Overall status
Completed
Start date
March 15, 2021
Completion date
December 14, 2023
Enrollment
1,025 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer